SCHEMBL1034033

SCHEMBL1034033

CCNc1nc(NCC)nc(NCC)n1

nearest known ligand 0.78

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.74
GAA P10253 3/20 0.61
CYP1A2 P05177 3/20 0.61
CYP2C19 P33261 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
POLB P06746 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
MCL1 Q07820 1/20 0.56
HTT P42858 2/20 0.52
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.47
ALOX15 P16050 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11741238 0.97 LMNA (0.70) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL8166873 0.88 LMNA (0.61) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL14869406 0.88 LMNA (0.61) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL821681 0.88 LMNA (0.61) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL10651511 0.86 LMNA (0.58) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL11788142 0.86 LMNA (0.58) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL4124952 0.86 LMNA (0.58) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL5011028 0.86 LMNA (0.58) LMNAGAACYP1A2CYP2C19L3MBTL1
SCHEMBL2623096 0.86 LMNA (0.58) LMNAGAACYP1A2CYP2C19L3MBTL1
Simazine SCHEMBL8409822 0.86 LMNA (1.00) LMNAGAACYP1A2CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0493788-B1 Three-layer vascular prosthesis MUDR MILAN KRAJICEK CSC (CS) 1996-09-25 EP claimed
EP-0493788-A1 Three-layer vascular prosthesis MUDR. MILAN KRAJICEK CSc. (CS) 1992-07-08 EP claimed
CN-119015258-A Nucleic acid mediated delivery of therapeutic agents 加利福尼亚大学董事会 2024-11-26 CN disclosed
CN-110325543-B Cyclic dinucleotides as STING (stimulator of interferon genes) agonists 武田药品工业株式会社 2023-03-31 CN disclosed
CN-110896605-B Use of compounds for the preparation of a medicament for the prevention, treatment or amelioration of pain 深圳艾欣达伟医药科技有限公司 2022-08-30 CN disclosed
CN-114746753-A Correlating AKR1C3 enzyme expression level through prostaglandin content and screening administration application 深圳艾欣达伟医药科技有限公司 2022-07-12 CN disclosed
CN-114555614-A Anti-cancer compounds as non-PGP substrates 深圳艾欣达伟医药科技有限公司 2022-05-27 CN disclosed
US-11044912-B2 Branched polymeric biguanide compounds and their uses CHEN HWANG HSING (US) 2021-06-29 US disclosed
US-10843967-B2 Road and surface coating compositions and processes thereof ePave, LLC (US) 2020-11-24 US disclosed
EP-3544963-B1 METHOD FOR ALKYLATING AN AMINO COMPOUND BOREALIS AGROLINZ MELAMINE (AT) 2020-11-04 EP disclosed
EP-3544963-B1 METHOD FOR ALKYLATING AN AMINO COMPOUND BOREALIS AGROLINZ MELAMINE (AT) 2020-11-04 EP disclosed
US-6127538-A HYDROXYALKYLATION OF A TRIAMINO TRIAZINE DERIVATIVE HAVING AT LEAST ONE REACTIVE NITROGEN BY REACTING WHILE HEATING WITH AN ALKANEDIOL OR ITS ADDUCT IN THE PRESENCE OF HYDROGEN AND A METAL CATALYST; BY-PRODUCT INHIBITION NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-10-03 US disclosed
US-6124381-A CURING ACCELERATOR IS A 2-((MONO- OR DI-ALKYL)AMINO, MORPHOLINO, PIPERIDINO, METHYL OR PHENYL)-4,6-SUBSTITUTED DIAMINO-1,3,5-TRIAZINE OF GIVEN FORMULA; POT LIFE, STORAGE STABILITY, AND WORKABILITY NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2000-09-26 US disclosed
EP-0882720-A1 METHODS FOR MODIFYING 1,3,5-TRIAZINE DERIVATIVES NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1998-12-09 EP disclosed
US-5792867-A Method of alkylating of triazine derivatives NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1998-08-11 US disclosed
EP-0834523-A1 EPOXY/ACID ANHYDRIDE COMPOSITION NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1998-04-08 EP disclosed
EP-0711760-A1 METHOD OF ALKYLATING TRIAZINE DERIVATIVE NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1996-05-15 EP disclosed
EP-0006206-B1 MELAMINE GROUP-CONTAINING ACRYLATES AND/OR METHACRYLATES, POLYMERIZABLE AND CURABLE COMPOSITION THEREOF, MOLDED ARTICLE MADE OF THE POLYMERIZED AND CURED COMPOSITION AND RESIN MOLDED ARTICLE COATED WITH THE COMPOSITION TEIJIN LIMITED (JP) 1982-11-24 EP disclosed
US-4186265-A BY EXTRACTION WITH AQUEOUS ACID OR BY ACIDIFICATION OF ALKALINE FILTRATE FOLLOWED BY EXTRACTION WITH WATER-IMMISCIBLE SOLVENT CIBA-GEIGY CORPORATION (US) 1980-01-29 US disclosed
US-3988292-A A TRIAZINE DERIVATIVE TEIJIN LIMITED (JA) 1976-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11044912-B2 Branched polymeric biguanide compounds and their uses PUF60, XRCC6, PCNA LMNA 2310/4885GAA 127/4885CYP1A2 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.